Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery
Monoclonal antibodies (mAbs) are increasingly exploited as vehicles for the targeted delivery of cytotoxic drugs. In antibody-drug conjugates (ADCs) antibodies specifically deliver cytotoxic compounds to cancer cells. Here, we present a technology for elevating the intracellular delivery of antibodi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
14 March 2020
|
| In: |
Journal of controlled release
Year: 2020, Jahrgang: 322, Pages: 200-208 |
| ISSN: | 1873-4995 |
| DOI: | 10.1016/j.jconrel.2020.03.005 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jconrel.2020.03.005 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0168365920301541 
|
| Verfasserangaben: | Max Sauter, Matthias Strieker, Christian Kleist, Artjom Wischnjow, Volker Daniel, Annette Altmann, Uwe Haberkorn, Walter Mier |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1752007484 | ||
| 003 | DE-627 | ||
| 005 | 20230427020249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210322s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2020.03.005 |2 doi | |
| 035 | |a (DE-627)1752007484 | ||
| 035 | |a (DE-599)KXP1752007484 | ||
| 035 | |a (OCoLC)1341399033 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sauter, Max |e VerfasserIn |0 (DE-588)1103516507 |0 (DE-627)86126813X |0 (DE-576)470642033 |4 aut | |
| 245 | 1 | 0 | |a Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery |c Max Sauter, Matthias Strieker, Christian Kleist, Artjom Wischnjow, Volker Daniel, Annette Altmann, Uwe Haberkorn, Walter Mier |
| 264 | 1 | |c 14 March 2020 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.03.2021 | ||
| 520 | |a Monoclonal antibodies (mAbs) are increasingly exploited as vehicles for the targeted delivery of cytotoxic drugs. In antibody-drug conjugates (ADCs) antibodies specifically deliver cytotoxic compounds to cancer cells. Here, we present a technology for elevating the intracellular delivery of antibodies by the conjugation of tetrameric cell-penetrating peptides (tCPPs). The solid phase synthesis of tCPPs and their application in a chemical modification strategy for mAbs provides constructs that attain up to fourfold elevated internalization rates while retaining the mAbs target specificity. The antigen independent internalization is accompanied by beneficial pharmacokinetics limiting off-target accumulation. Applicability was proven for matuzumab, trastuzumab and the ADC Kadcyla®. Cytotoxicity studies of tCPP-conjugates of Kadcyla® resulted in a sixfold increased cytotoxicity proving the potential of chemical modification strategies to extend the applicability of biologicals. This constitutes a significant step towards next-generation antibody-based therapeutics. | ||
| 650 | 4 | |a Antibody-drug conjugates | |
| 650 | 4 | |a Bioconjugation | |
| 650 | 4 | |a Cell-penetrating peptides | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Solid phase peptide synthesis | |
| 700 | 1 | |a Strieker, Matthias |d 1981- |e VerfasserIn |0 (DE-588)132308509 |0 (DE-627)521414423 |0 (DE-576)299065332 |4 aut | |
| 700 | 1 | |a Kleist, Christian |e VerfasserIn |0 (DE-588)138977410 |0 (DE-627)703170287 |0 (DE-576)309272971 |4 aut | |
| 700 | 1 | |a Wischnjow, Artjom |e VerfasserIn |0 (DE-588)1128443740 |0 (DE-627)882926349 |0 (DE-576)485914603 |4 aut | |
| 700 | 1 | |a Daniel, Volker |e VerfasserIn |0 (DE-588)1058939513 |0 (DE-627)79784418X |0 (DE-576)166309168 |4 aut | |
| 700 | 1 | |a Altmann, Annette |e VerfasserIn |0 (DE-588)1032267984 |0 (DE-627)738189111 |0 (DE-576)379930099 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release |d New York, NY [u.a.] : Elsevier, 1984 |g 322(2020) vom: Juni, Seite 200-208 |h Online-Ressource |w (DE-627)300589220 |w (DE-600)1482453-X |w (DE-576)081952589 |x 1873-4995 |7 nnas |a Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery |
| 773 | 1 | 8 | |g volume:322 |g year:2020 |g month:06 |g pages:200-208 |g extent:9 |a Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jconrel.2020.03.005 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0168365920301541 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210322 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |d 140000 |e 910000PM12029026X |e 911400PM12029026X |e 140000PM12029026X |k 0/910000/ |k 1/910000/911400/ |k 0/140000/ |p 8 |y j | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 1032267984 |a Altmann, Annette |m 1032267984:Altmann, Annette |d 910000 |d 911400 |e 910000PA1032267984 |e 911400PA1032267984 |k 0/910000/ |k 1/910000/911400/ |p 6 | ||
| 998 | |g 1058939513 |a Daniel, Volker |m 1058939513:Daniel, Volker |d 910000 |d 911600 |d 50000 |e 910000PD1058939513 |e 911600PD1058939513 |e 50000PD1058939513 |k 0/910000/ |k 1/910000/911600/ |k 0/50000/ |p 5 | ||
| 998 | |g 138977410 |a Kleist, Christian |m 138977410:Kleist, Christian |d 910000 |d 911400 |e 910000PK138977410 |e 911400PK138977410 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 1103516507 |a Sauter, Max |m 1103516507:Sauter, Max |d 910000 |d 910100 |e 910000PS1103516507 |e 910100PS1103516507 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1752007484 |e 3892391335 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Max Sauter, Matthias Strieker, Christian Kleist, Artjom Wischnjow, Volker Daniel, Annette Altmann, Uwe Haberkorn, Walter Mier"]},"recId":"1752007484","id":{"doi":["10.1016/j.jconrel.2020.03.005"],"eki":["1752007484"]},"title":[{"title_sort":"Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery","title":"Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery"}],"person":[{"role":"aut","family":"Sauter","roleDisplay":"VerfasserIn","given":"Max","display":"Sauter, Max"},{"role":"aut","family":"Strieker","roleDisplay":"VerfasserIn","display":"Strieker, Matthias","given":"Matthias"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Christian","display":"Kleist, Christian","family":"Kleist"},{"role":"aut","family":"Wischnjow","display":"Wischnjow, Artjom","roleDisplay":"VerfasserIn","given":"Artjom"},{"family":"Daniel","roleDisplay":"VerfasserIn","given":"Volker","display":"Daniel, Volker","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Annette","display":"Altmann, Annette","family":"Altmann","role":"aut"},{"family":"Haberkorn","roleDisplay":"VerfasserIn","given":"Uwe","display":"Haberkorn, Uwe","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Walter","display":"Mier, Walter","family":"Mier"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"14 March 2020","dateIssuedKey":"2020"}],"language":["eng"],"physDesc":[{"extent":"9 S."}],"relHost":[{"note":["Gesehen am 03.06.08"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular deliveryJournal of controlled release","language":["eng"],"origin":[{"dateIssuedKey":"1984","dateIssuedDisp":"1984-","publisher":"Elsevier","publisherPlace":"New York, NY [u.a.]"}],"corporate":[{"display":"Controlled Release Society","roleDisplay":"Herausgebendes Organ","role":"isb"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"322","text":"322(2020) vom: Juni, Seite 200-208","extent":"9","year":"2020","pages":"200-208"},"title":[{"title_sort":"Journal of controlled release","title":"Journal of controlled release","subtitle":"official journal of the Controlled Release Society and of the Japanese Society of Drug Delivery Systems"}],"id":{"issn":["1873-4995"],"eki":["300589220"],"zdb":["1482453-X"]},"recId":"300589220","pubHistory":["1.1984/85 - 172.2013; Vol. 173.2014 -"]}],"note":["Gesehen am 22.03.2021"]} | ||
| SRT | |a SAUTERMAXSIMPROVINGA1420 | ||